CAN1012

DRUG5 trials

Sponsors

CanWell Pharma Inc., Canwell Biotech Limited, Providence Health & Services

Conditions

Advanced Solid TumorCancer MetastaticDuctal Carcinoma in SituLobular Carcinoma in SituOral Epithelial Dysplasia (OED)Solid Tumor

Phase 1

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

CanWell Pharma Inc.Cancer Metastatic, Solid Tumor

Start: 2022-01-20End: 2024-12-30Target: 36Updated: 2023-12-22

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Active, not recruitingNCT05580991

Canwell Biotech LimitedSolid Tumor

Start: 2022-09-09End: 2025-06-30Updated: 2025-02-13

CAN1012 Combined With PD-1 in Patients With Solid Tumors

RecruitingNCT06410703

Canwell Biotech LimitedAdvanced Solid Tumor

Start: 2024-06-27End: 2026-05-30Target: 71Updated: 2024-10-31

CAN1012 in Pre-Malignant DCIS and LCIS

Not yet recruitingNCT07408856

Providence Health & ServicesDuctal Carcinoma in Situ, Lobular Carcinoma in Situ

Start: 2026-08-01End: 2035-05-01Target: 24Updated: 2026-07-23

CAN1012 in Pre-malignant Oral Dysplasia

Not yet recruitingNCT07620496

Providence Health & ServicesOral Epithelial Dysplasia (OED)

Start: 2026-07-01End: 2033-07-01Target: 36Updated: 2026-06-02

Related Papers

763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies

Regular and Young Investigator Award Abstracts2023-10-31

1171 CAN1012: a selective and potent TLR7 agonist with strong antitumoral properties mediated by localized innate immune activation

Regular and Young Investigator Award Abstracts2022-11-012 citations